The gap between the two compounds is unusually small
Across this category, tirzepatide almost always costs meaningfully more than semaglutide. At Trimi the two sit close together.
That matters for a specific reader: someone who starts on semaglutide and may want to switch. At most sellers here that switch carries a price increase. At Trimi it is a small step.
It also means Trimi looks strongest on the tirzepatide board and less remarkable on the semaglutide one. Read its position on each board separately rather than treating one as a verdict on the platform.
Both prices assume you commit to a year
Trimi's published figures are annual-plan rates. That condition is printed beside the numbers rather than hidden, and the site is consistent about it across pages.
What is missing is the alternative. A month-to-month rate appears on none of Trimi's treatments page, its FAQ or its cost guide. So the cost of a shorter commitment is not something a reader can price before intake.
A prepaid year is a real bet for a first-time patient. It assumes the medication suits you, that you tolerate it, and that you want to continue. Ask what leaving in month two costs before treating the annual rate as your price.
What the price is stated to include
Trimi says the rate holds flat across dose levels and covers free shipping, unlimited provider messaging and ongoing dose adjustments.
Flat dosing is the more valuable half. A patient titrating upward is not walking into a price increase, which is not true at every seller in this comparison.
Trimi also names the clinician network behind its prescriptions rather than describing it in general terms. That is more specific than most of this field, though it is a clinical network rather than a pharmacy.
Trimi publishes a table ranking its competitors
Trimi runs a cost guide that names rival providers and prints figures for them, then concludes that Trimi is the cheapest legitimate option.
At least one competitor rate in that table sits well above what the competitor advertises on its own site today. Both sides were read directly. The gap is large enough to change which provider looks cheaper.
None of that is unusual for a seller's own comparison page, and it does not say anything about Trimi's medication. It does say something about the source. A provider's table of its rivals is marketing, and it should not be used as a price reference for anyone but Trimi.
What Trimi does not publish
Trimi does not name the compounding pharmacy that fills an order. The clinical network is named; the pharmacy is not.
No registered legal entity appears on the pages read, either. The brand is used throughout the terms without a company name behind it, which is thinner disclosure than most sellers in this comparison offer.
Trimi does publish an unusually large library of cost, comparison and dosing material. Volume of content is not the same as disclosure about the company itself.
Trimi Health's published pricing
compareglp may earn a commission when a reader signs up with a provider through a link on this site. None of the 16 providers reviewed here are paid partners today. See how this works.
See Trimi Health's current price →Good fit if
- Patients who want tirzepatide without the premium most sellers in this comparison attach to it.
- Readers who expect to titrate upward and want the price to stay flat as the dose climbs.
- People confident enough to commit to a year, since that is the only term Trimi prices publicly.
- Readers who want nationwide availability at one rate rather than a price that varies by location.
Look elsewhere if
- Anyone who wants to start month to month. No month-to-month rate appears on Trimi's treatments, FAQ or cost-guide pages.
- Patients who need the compounding pharmacy named before ordering.
- Readers who want to know which company stands behind the brand. No registered entity appears on the pages read.
- Anyone treating Trimi's competitor comparison table as a neutral price source, since at least one rival figure in it is above that rival's own advertised rate.
How this review was verified
- Read Trimi's treatments page at its source URL and logged both published figures with the date each was read.
- Carried the annual-plan condition into the qualifier on both figures, so the plan term cannot be separated from the number in a comparison table.
- Read the FAQ and the cost guide as well as the treatments page to establish whether a month-to-month rate is published anywhere. All three carry only the annual-plan rate.
- Checked Trimi's nationwide availability claim against the wording published on its own FAQ.
- Compared one competitor figure in Trimi's cost guide against that competitor's own live pricing page on the same day. The two do not agree, and the difference is reported rather than resolved.